Darby S C, Ewart D W, Giangrande P L, Spooner R J, Rizza C R
Cancer Epidemiology Unit, Oxford University, Radcliffe Infirmary, UK.
Lancet. 1996 Jun 8;347(9015):1573-9. doi: 10.1016/s0140-6736(96)91073-9.
Greater age at infection with HIV-1 is known to be associated with shorter time to development of AIDS, but the size of the differences between people infected in infancy and those infected in old age has not been examined in a single large population of patients with death as an endpoint. We, therefore, investigated the role of age at seroconversion in the entire UK population of haemophiliacs.
We studied 1216 HIV-1-infected haemophilia patients in the UK who were registered with the National Haemophilia Register and were alive on Jan 1, 1985. Their estimated ages at HIV-1 seroconversion ranged from 8 months to 79 years.
10 years after seroconversion 67% (95% Cl 64-69) of the population were still alive. Survival was strongly related to age at seroconversion (86% [82-90], 72% [68-76], 45% [39-51], and 12% [5-21] at 10 years among those patients who seroconverted at ages < 15, 15-34, 35-54, and > or = 55). This steep age-gradient in survival was not explained by deaths expected in the absence of HIV infection or by confounding with other factors such as haemophilia type or severity. The age-gradient was steeper for survival (ie, time from HIV-1 infection to death) than for time to diagnosis of AIDS, partly because survival after an AIDS diagnosis was poorer in older patients, and there was also a substantial increase in mortality among HIV-infected patients who did not satisfy the formal AIDS definition and this increase was greater in older patients.
Age at infection with HIV-1 is a more important determinant of survival than has previously been appreciated. Age should, therefore, be considered in future studies of disease progression, and studies that compare people infected at different ages should provide insight into the biology of the immune response to HIV-1.
已知感染HIV-1时年龄越大,发展为艾滋病的时间越短,但在以死亡为终点的单一大型患者群体中,尚未对婴儿期感染与老年期感染人群之间差异的大小进行研究。因此,我们调查了血清转化年龄在英国全体血友病患者中的作用。
我们研究了1216名在英国感染HIV-1的血友病患者,这些患者在国家血友病登记处登记,且在1985年1月1日时存活。他们估计的HIV-1血清转化年龄在8个月至79岁之间。
血清转化10年后,67%(95%置信区间64 - 69)的人群仍然存活。生存率与血清转化年龄密切相关(血清转化年龄<15岁、15 - 34岁、35 - 54岁和≥55岁的患者在10年时的生存率分别为86%[82 - 90]、72%[68 - 76]、45%[39 - 51]和12%[5 - 21])。这种生存率上随年龄急剧变化的梯度不能用未感染HIV时预期的死亡情况来解释,也不能用与其他因素(如血友病类型或严重程度)的混杂来解释。生存率(即从HIV-1感染到死亡的时间)的年龄梯度比艾滋病诊断时间的年龄梯度更陡,部分原因是老年患者艾滋病诊断后的生存率较差,而且在未符合正式艾滋病定义的HIV感染患者中死亡率也大幅上升,且这种上升在老年患者中更大。
感染HIV-1时的年龄是比之前所认识到的更重要的生存决定因素。因此,在未来疾病进展研究中应考虑年龄因素,比较不同年龄感染人群的研究应能深入了解对HIV-1免疫反应的生物学机制。